Get all your news in one place.
100's of premium titles.
One app.
Start reading
Zenger
Zenger
Benjamin Raizel

As Nuclear Threat Grows, Israeli Biotech Company Signs $4.2M Contract With U.S. Military, Health Age

A representation of A representation of the PLX-R18 cell therapy as a treatment for Hematopoietic Acute Radiation Syndrome (H-ARS), developed in Haifa, Israel. (Courtesy of Pluri)

A revolutionary treatment for radiation poisoning may be on the horizon, as threats of nuclear warfare continue to reverberate from Moscow.

Pluri Inc. (NASDAQ:PLUR), an Israeli biotechnology company specializing in cell expansion, on Tuesday announced a new partnership with U.S. health and military agencies to continue developing the company’s PLX-R18 cell therapy as a treatment for Hematopoietic Acute Radiation Syndrome (H-ARS), which can result from exposure to nuclear fallout. The National Institute of Allergy and Infectious Diseases (NIAID) awarded Pluri and the Department of Defense’s Armed Forces Radiobiology Research Institute (AFRRI) a contract worth $4.2 million in total to advance the potential breakthrough cell therapy. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.